Breaking News

INC Research Appoints Clinical Pharmacology VP

By Kristin Brooks | February 7, 2014

Setnik to support Early Phase unit on abuse liability

Beatrice Setnik, Ph.D., has been appointed vice president of Clinical Pharmacology at INC Research. Dr. Setnik will support the Early Phase Business Unit, providing scientific direction on abuse liability.
Dr. Setnik joins the company from Pfizer, where she served as senior director of Medical Development-Neuroscience, leading clinical development, including abuse potential evaluation of several opioid formulations. Prior to Pfizer, she worked as a research scientist providing scientific input on specialty Phase I-II trials, including abuse potential studies. Dr. Setnik chairs the clinical sub-team within the Cross Company Abuse Liability Consortium and has been an active member in the group since 2008.
“We are delighted to welcome Beatrice to our clinical pharmacology team,” said Dr. Pierre Geoffroy, vice president, Early Phase at INC Research. “Dr. Setnik’s extensive knowledge and experience in the area of human abuse liability assessment and risk evaluation, as well as in CNS drug development, clinical trial design and strategic lifecycle management, will be instrumental in furthering the development of our abuse potential capabilities and new scientific growth strategies for early phase clinical research.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important